1. Medicine

Category Archives: Medicine

Medicine Lodge residents told to boil water

Posted on by

The Kansas Department of Health and Environment has issued a boil water advisory for the city of Medicine Lodge, according to a news release Monday.

The citys water supply had a malfunction in its chlorine injection system. The advisory is effective immediately.

The KDHE said in its release that residents should use the following precautions until further notice:

Boil water for one minute before drinking it or for food preparation.

Dispose of ice cubes and do not use ice from an automatic ice maker.

Disinfect dishes and other food contact surfaces by immersion for at least one minute in clean tap water that contains one teaspoon of unscented household bleach per gallon of water.

Water used for bathing does not need to be boiled. Supervision of children while bathing is necessary so that the water is not ingested.

A person with cuts or severe rashes may want to consult their physicians. If tap water appears dirty, flush the water lines by letting the water run until it clears.

The KDHE or local officials will make an announcement when the advisory has been lifted.

For more information, contact Darrel Plummer at 785-296-5523.

Go here to see the original:

Medicine Lodge residents told to boil water

PathCentral’s New Digital Pathology Network Expands With Participation by Penn Medicine

Posted on by

IRVINE, Calif.--(BUSINESS WIRE)--

PathCentral (www.pathcentral.net), a technology-enabled company dedicated to the success of the international pathology community, announced today that Penn Medicine will participate in the PathCentral Pathology Network (www.pathcentralpro.net), the specialtys most comprehensive online information exchange and digital consultation forum.

The PathCentral Pathology Network will provide Penn Medicine pathologists with new opportunities to collaborate on cases on a global basis, said David B. Roth, MD, PhD., Chair of the Penn Medicine Department of Pathology and Laboratory Medicine. Digital pathology is poised to expand the reach of every pathologist beyond his or her backyard to patients and practices the world over.

The PathCentral Pathology Network enables physicians to upload case files using digital images for pathologists to review and render critical consulting diagnoses on both a global and a domestic real-time basis. In terms of scanning technology and imaging software, the Network is agnostic and designed to be non-exclusive that is, open to all users regardless of location or consulting institution. The PathCentral Pathology Network seeks to connect the worlds pathologists, incorporating tools from social media, making it an ideal forum for pathologists to send and perform consults, create connections, post information, share cases, ask questions, and expand professional relationships.

About PathCentral

Through its comprehensive suite of products and services, PathCentral provides independent community-based pathologists with the tools they need to increase revenues, improve operating efficiencies, ensure patient safety, and become highly competitive in their local markets. With its blend of leading edge IT web computing technology and global connectivity, PathCentral enables pathologists around the world to grow, thrive and more effectively meet the demands of 21st Century diagnostic medicine. For more information, please visit http://www.pathcentral.net; for information on the PathCentral Pathology Network, visit http://www.pathcentralpro.net.

See the rest here:

PathCentral’s New Digital Pathology Network Expands With Participation by Penn Medicine

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugate …

Posted on by

SAN DIEGO and SHANGHAI, June 16, 2013 /PRNewswire/ -- Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

Under the agreement, Ambrx and ZMC will continue the development of ARX788, with ZMC bearing the ongoing development cost. ZMC will receive commercial rights in China while Ambrx retains commercial rights outside of China and receives royalties on sales of the product in China. ZMC will manufacture the product to world-class standards for clinical and commercial supplies on a global basis. WuXi PharmaTech will provide integrated services for ARX788, including the development and manufacturing of the toxin, antibody and ADC, pre-clinical development and clinical trials.

"We are excited to initiate this unique collaboration with ZMC and WuXi, which allows us to team up with China's leading pharmaceutical and CRO companies to efficiently develop ARX788, our most advanced ADC therapeutic candidate for both breast cancer and gastric cancer indications," said Lawson Macartney, Ph.D., Chief Executive Officer of Ambrx. "This collaboration allows Ambrx to further extend our pipeline of ADCs and gain access to the China market through our partnership with ZMC. Our experience with site-specific ADC technology has shown that we have the potential to create best-in-class therapeutic candidates, and we look forward to advancing ARX788 into the clinic to understand its full potential."

Chunbo Li, Chairman of Zhejiang Medicine, commented, "We are honored to partner with Ambrx, a leading biotech company, in ADC drugs. We will work with WuXi PharmaTech to accelerate the development and commercialization of ARX788 in China to bring benefits to Her2-positive cancer patients. The partnership will help ZMC undertake pioneering work in the development of monoclonal antibodies and ADCs. The partnership will also help ZMC establish long-term and mutually beneficial relationships with leading global companies and advance our position in the biopharmaceutical industry."

"Our collaboration with Ambrx and ZMC on ARX788 is another example of how WuXi's comprehensive, integrated, open-access R&D services platform enables our partners to develop innovative products efficiently and cost-effectively to benefit the world's patients," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "We are very pleased to offer our partners integrated services at global standards ranging from toxins to antibodies, from CMC development to pre-clinical studies, from regulatory strategy to clinical trials."

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including ADCs, bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. In addition to its most recent ADC collaborations with Merck, Astellas and Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol-Myers Squibb, Eli Lilly and several undisclosed companies. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.

For additional information, visit http://www.ambrx.com.

About Zhejiang Medicine Co. Ltd.

Zhejiang Medicine Co. Ltd. (ZMC) is a major China-based pharmaceutical company listed on the Shanghai stock exchange. It is a leading global manufacturer of fat-soluble vitamins and bacteria-resistant antibiotics. ZMC's products are exported to the United States and many EU countries. In 2012, total revenue reached 5.3 billion RMB and total profit reached 855 million RMB. ZMC has strong capabilities in technology innovation and new drug R&D and has received the National High-Tech Enterprise and Model Innovation Enterprise awards in China. ZMC has a national-level R&D center and post-doctorate R&D sponsorship. Three ZMC research projects were awarded second prize in the National Technology Advancement competition and one was awarded second prize in the National Technology Innovation competition. To date, ZMC has 126 issued patents, including 15 global patents, and has four class 1 drugs in clinical trials.

Visit link:

Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate ...

Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor …

Posted on by

NEW YORK, June 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)

http://www.reportlinker.com/p01360928/Personalized-Medicine-Diagnostics-Flow-Cytometry-Sepsis-Immunos-Routine-Coagulation-Psychiatric-Disorders-Tumor-Markers-Molecular-Blood-Typing-and-Other-Testing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Personalized Medicine Diagnostics - Market Overview

Personalized Medicine is often defined as "the right treatment for the right person at the right time." Personalized medicine is becoming the place to be in clinical diagnostics as well and slowly becoming the reality of future in the diagnostics industry

By Technology Segment - Personalized Medicine diagnostics market is expected to grow with a double digit CAGR for the period of 2013 to 2018. It is expected that personalized medicine diagnostics market by technology is going to double by 2018 from its current market size in 2012. In this segment, Point of Care Testing and Molecular Diagnostics segments control the #1 and #2 positions in 2012.

By Diseases Segment - Personalized Medicine diagnostics market is expected to be more than US$ 30 Billion by 2018. Diabetes management test and Cancer management test are the leading market in this segment.

Renub Research report entitled "Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)" report provides a comprehensive analysis of the emerging personalized medicine diagnostic market segments, including their dynamics, size, market share, key investors, clinical trials statement, technological trends, company analysis and a realistic future potential for personalized medicine in clinical testing. The report also entails major drivers and challenges of personalized medicine diagnostic market. This 173 page report contains 94 Figures and 16 Tables studies the Personalized Medicine Diagnostics Market. This report contains 12 chapters

Chapter 1 is Executive Summary

Chapter 2 contains worldwide personalized medicine diagnostic market & forecast (2011 2018). The market includes technological & disease-wise personalized medicine diagnostics market

Continue reading here:

Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor ...

The Science of Mesenchymal Stem Cells and Regenerative Medicine – Arnold Caplan PhD (Part 2) – Video

Posted on by


The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 2)
In part 2, Prof. Caplan discusses the two types of regenerative medicine: tissue engineering and in vivo tissue regeneration, hematapoietic and mesenchymal s...

By: http://www.cellmedicine.com

Read the rest here:

The Science of Mesenchymal Stem Cells and Regenerative Medicine - Arnold Caplan PhD (Part 2) - Video

Dr. Paul Rothman | The Office of Women in Science and Medicine (OWISM) Luncheon – Video

Posted on by


Dr. Paul Rothman | The Office of Women in Science and Medicine (OWISM) Luncheon
Dr. Paul Rothman, Dean and CEO of Johns Hopkins Medicine, speaks at a luncheon for The Office of Women in Science and Medicine (OWISM) on November 27, 2012.

By: JohnsHopkinsMedicine

Read the original post:

Dr. Paul Rothman | The Office of Women in Science and Medicine (OWISM) Luncheon - Video

Phoenix Wright: Trials and Tribulations – Ep. 3, Part 10: Missing Prescription Medicine – Video

Posted on by


Phoenix Wright: Trials and Tribulations - Ep. 3, Part 10: Missing Prescription Medicine
A video walkthrough for Phoenix Wright: Ace Attorney: Trials and Tribulations (also known as Phoenix Wright 3) for the Nintendo DS. Episode 3: Recipe for Tur...

By: arglefumph

Read more:

Phoenix Wright: Trials and Tribulations - Ep. 3, Part 10: Missing Prescription Medicine - Video


  1. Medicine